These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 30287855

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
    Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ, PROUD-PV Study Group.
    Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
    Wagner SM, Melchardt T, Greil R.
    Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866
    [Abstract] [Full Text] [Related]

  • 5. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
    Qin A, Wu D, Li Y, Zhang J, Wang W, Shen W, Liao J, Lin S, Chang C, Chen H, Cui J, Su X.
    Br J Clin Pharmacol; 2024 Jun; 90(6):1493-1502. PubMed ID: 38500445
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
    Jin J, Qin A, Zhang L, Shen W, Wang W, Zhang J, Li Y, Wu D, Xiao Z.
    Future Oncol; 2023 Apr; 19(11):753-761. PubMed ID: 37129584
    [Abstract] [Full Text] [Related]

  • 10. Disappearance of a chromosomal abnormality in a young patient with polycythemia vera treated with ropeginterferon alfa-2b.
    Hosoda R, Hashimoto Y, Hara K, Maegaki M, Suzuki S, Hosoda Y, Kawamura K.
    Ann Hematol; 2024 Sep; 103(9):3825-3827. PubMed ID: 39052033
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
    Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, Usuki K, Shimoda K, Ito M, VanWart SA, Zagrijtschuk O, Qin A, Kawase H, Miyachi N, Sato T, Komatsu N, Kirito K.
    Int J Hematol; 2022 Aug; 116(2):215-227. PubMed ID: 35430707
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment.
    Qin A.
    Clin Ther; 2024 May; 46(5):439-440. PubMed ID: 38697872
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V, Misurin AV, Michiels JJ, Rozenberg JM, Sokolova MA, Ivanova VL, Kolosheinova TI, Manakova TE, Levina AA, Semenova EA, Khoroshko ND.
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Novel germline JAK2R715T mutation causing PV-like erythrocytosis in 3 generations. Amelioration by Ropeg-Interferon.
    Song J, Lanikova L, Kim SJ, Papadopoulos N, Meznarich J, Constantinescu SN, Parsegov B, Prchal JF, Prchal JT.
    Am J Hematol; 2024 Jul; 99(7):1220-1229. PubMed ID: 38629639
    [Abstract] [Full Text] [Related]

  • 20. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.
    Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, Menot ML, Massonnet G, Dutel JL, Ghomari K, Rousselot P, Grange MJ, Chait Y, Vainchenker W, Parquet N, Abdelkader-Aljassem L, Bernard JF, Rain JD, Chevret S, Chomienne C, Fenaux P.
    Blood; 2006 Sep 15; 108(6):2037-40. PubMed ID: 16709929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.